LABTNasdaq

Lakewood-Amedex Biotherapeutics Inc.

Healthcare·Healthcare·University Park, FL, United States

Lakewood-Amedex Biotherapeutics Inc. (LABT): 89 pipeline candidates · ~0 mo cash runway. Updated within the last hour.

6.7/10

BioSniper Score

3-factor signal · derived from public data

Cash Runway0.1

0.2 months

Financial Health10.0

D/E -1.07 · 0% dilution

Pipeline MaturityN/A

N/A

Pipeline Breadth10.0

89 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Lakewood-Amedex Biotherapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$8.5M

Cash

$12K

Quarterly Burn

$350K

Runway

0.2 mo

Revenue

—

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jun 2026
Today~7 mo out
Catalyst within runway

Pipeline (89 candidates)

DrugPhase
brain heart infus agar slant w/10% sheep blood c&c—
brain heart infus agar slant w/6% sb chloramphenic—
brain heart infus agar slt w/5% sheep blood #t3286—
brain heart infus agar slt w/5% sheep blood/gentam—
brain heart infus agar w/5% sb & chloramphenicol—
brain heart infus agar w/5% sb & gentamicin-#p3772—
brain heart infus agar w/5% sb penicillin/streptom—
brain heart infus agr slt w/5% shp bld penic/strep—
brain heart infusion agar - bhia product #p3302—
brain heart infusion agar iii - product #p3590—

Showing 10 of 89 candidates. Sign up for full pipeline.

·CEO: Dr. Kelvin Cooper Ph.D.

Frequently asked questions

How many drug candidates are in Lakewood-Amedex Biotherapeutics Inc.'s pipeline?

Lakewood-Amedex Biotherapeutics Inc. (LABT) has 89 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Lakewood-Amedex Biotherapeutics Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Lakewood-Amedex Biotherapeutics Inc. has approximately 0.2 months of cash runway.

What is Lakewood-Amedex Biotherapeutics Inc.'s market capitalization?

Lakewood-Amedex Biotherapeutics Inc.'s market capitalization is approximately $8.5M.

Who is the CEO of Lakewood-Amedex Biotherapeutics Inc.?

Dr. Kelvin Cooper Ph.D. is the chief executive officer of Lakewood-Amedex Biotherapeutics Inc. (LABT).

Get the full picture on Lakewood-Amedex Biotherapeutics Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar